Rituximab vs placebo: Disability worsening
- Population
- primary progressive multiple sclerosis
- Intervention
- Rituximab
- Comparison
- placebo
- Outcome
- Disability worsening
Rituximab as 'first choice' showed no clear difference in disability worsening measured by EDSS over 24 months compared with placebo (moderate certainty).
What each review found
Include earlier review versions| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
Rituximab as 'first choice' vs placebo Disability worsening measured by EDSS over 24 months · primary progressive multiple sclerosis Rituximab as 'first choice' showed no clear difference in disability worsening measured by EDSS over 24 months compared with placebo (moderate certainty). Rituximab for people with multiple sclerosis (2021) · Cochrane Headline outcomes only | OR 0.71 [0.45, 1.11] | 1 study · 439 participants | Moderate |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| Rituximab for people with multiple sclerosis 2021 · Cochrane Headline outcomes only | Not reported | Not extracted | Not assessed |
Related questions
The same intervention and outcome, asked in another population or against another comparator.
- Rituximab vs placebo · relapsing multiple sclerosis · 1 review
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.